Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Jazz Pharmaceuticals plc JAZZ

Healthcare
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn... see more

NDAQ:JAZZ - Post Discussion

Jazz Pharmaceuticals plc > Cannabinoid Pharma
View:
Post by Bullknit101 on Sep 30, 2021 8:17am

Cannabinoid Pharma

To my knowledge, InMed Pharma is the only company conducting clinical trials with rare cannabinoids which they can also manufacture. Epidiolex is CBD ia based. https://www.globenewswire.com/news-release/2021/09/30/2306088/36215/en/InMed-Pharmaceuticals-Announces-Commencement-of-Phase-2-Clinical-Trial-Investigating-Cannabinol-CBN-a-Rare-Cannabinoid-in-the-Treatment-of-Epidermolysis-Bullosa.html
Comment by alleyesonme on Jun 04, 2024 12:00pm
According to Jazz’s filings, in October 2023, it settled with Padagis US LLC and granted Padagis a license to manufacture, market, and sell its generic version of Epidiolex on a date that depends on the occurrence of certain other events.....medipharm labs is in an undisclosed partnership on a ANDA for the epidiolex generic...president stated earlier in the year they are preparing for launch..I ...more  
Jazz Pharmaceuticals plc